EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain.

Jordi Navarro, Adrian Curran, Berta Raventós, Jorge García, Paula Suanzes, Vicente Descalzo, Patricia Álvarez, Nuria Espinosa, Marisa Luisa Montes, Inés Suárez-García, Concha Amador, Roberto Muga und 3 weitere

European Journal of Internal Medicine · 2023

DOI: 10.1016/j.ejim.2023.01.028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Internal Medicine, 2023. Verfasst von Jordi Navarro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Institut de Recerca Vall d'Hebron, Barcelona, Spain. Electroni…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most important liver comorbidities in people living with HIV (PLWH). Factors that could lead to a higher prevalence of NAFLD or ease the onset of fibrosis are unclear. METHODS: Cohort study of the Spanish HIV Research Network, which comprehends 46 hospitals and more than 15,000 PLWH. Primary objectives were to assess NAFLD prevalence and liver fibrosis according to hepatic steatosis index (HSI) and NAFLD fibrosis score, respectively. Factors associated with both were analysed. RESULTS: A total of 4798 PLWH were included of whom 1461 (30.5%) showed an HSI>36; these patients had higher risk for significant fibrosis (OR 1.91; 95%CI 1.11-3.28). Factors associated with NAFLD were body mass index (OR 2.05; 95%CI 1.94-2.16) and diabetes (OR 4.68; 95%CI 2.17-10.08), while exposure to integrase strand transfer inhibitors showed a lower risk (OR 0.78; 95%CI 0.62-0.97). In patients with HSI>36, being female (OR 7.33; 95%CI 1.34-40), age (OR 1.22; 95%CI 1.11-1.34), body mass index (OR 1.35; 95%CI 1.18-1.54) and exposure to thymidine analogues (OR 75.4, 95%CI 6.9-823.5) were associated with a higher risk of significant fibrosis. However, exposure to non-nucleoside reverse transcriptase inhibitors (OR 0.12, 95%CI 0.02-0.89) and time of exposure to protease inhibitors (OR 0.97, 95%CI 0.95-1) showed a lower risk. CONCLUSION: NAFLD prevalence was high in our cohort. Patients exposed to INSTI showed a lower risk of NAFLD. In patients with hepatic steatosis, exposure to thymidine analogues had 75-fold more risk of significant fibrosis while exposure to NNRTIs reduced this risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHIV InfectionsHumansFemaleMalePrevalenceCohort StudiesSpainLiver Cirrhosis

Stichwörter der Autor:innen

Antiretroviral therapyFatty liverHIV-infectionLiver fibrosisNAFLD

Autor:innen und Institutionen

  • Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Institut de Recerca Vall d'Hebron, Barcelona, Spain. Electronic address: jordi.navarro@vallhebron.cat.
  • Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Institut de Recerca Vall d'Hebron, Barcelona, Spain. Electronic address: adrian.curran@vallhebron.cat.
  • Institut de Recerca Vall d'Hebron, Barcelona, Spain; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Institut de Recerca Vall d'Hebron, Barcelona, Spain.
  • Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva, Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
  • Unidad VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, IdiPaz, Madrid, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Navarro, J., Curran, A., Raventós, B., García, J., Suanzes, P., Descalzo, V., Álvarez, P., Espinosa, N., Montes, M. L., Suárez-García, I., Amador, C., Muga, R., Falcó, V., Burgos, J., & Spanish HIV Research Network (CoRIS) (2023). Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2023.01.028

Vancouver

Navarro J, Curran A, Raventós B, García J, Suanzes P, Descalzo V, et al. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain. European Journal of Internal Medicine. 2023. doi:10.1016/j.ejim.2023.01.028

BibTeX
@article{Navarro2023,
  author = {Navarro, Jordi and Curran, Adrian and Raventós, Berta and García, Jorge and Suanzes, Paula and Descalzo, Vicente and Álvarez, Patricia and Espinosa, Nuria and Montes, Marisa Luisa and Suárez-García, Inés and Amador, Concha and Muga, Roberto and Falcó, Vicenç and Burgos, Joaquín and Spanish HIV Research Network (CoRIS), Spanish HIV Research Network (CoRIS)},
  title = {Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain},
  journal = {European Journal of Internal Medicine},
  year = {2023},
  doi = {10.1016/j.ejim.2023.01.028}
}
Kostenlos starten →